Patented prostate cancer biomarkers

Nature Reviews Urology

Volumn 9, Issue 8, 2012, Pages 464-472

  Murphy, Lisa ^a   Watson, R William ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CAVEOLIN 1; CREATINE KINASE; GLUTATHIONE TRANSFERASE P1; GLYCAN; INSULIN GROWTH FACTOR 1; MIGRATION INHIBITION FACTOR; PROSTATCE CANCER DIAGNOSTIC MARKER 1; PROSTATE CANCER ANTIGEN 1; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; CANCER SURVIVAL; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN SITU HYBRIDIZATION; METASTASIS; PATENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; BLOOD; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

HUMANS; KALLIKREINS; MALE; PATENTS AS TOPIC; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864887491     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.130     Document Type: Review

References (82)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Shariat, S. F. et al. Tumour markers in prostate cancer I: blood based markers. Acta. Oncol. 50 (Suppl. 1), 61-75 (2011).
3. Jackson, T. et al. Disclosure of diagnosis and treatment among early stage prostate cancer survivors. Patient Educ. Couns. 79, 239-244 (2010).
4. Cancer Facts & Figures 2009. American Cancer Society [online], http://www.cancer.org/acs/groups/content/@nho/documents/document/500809webpdf. pdf (2009).
5. Lukes, M. et al. Prostate-specific antigen: current status. Folia Biol. (Praha) 47, 41-49 (2001). (Pubitemid 32266550)
6. Allhoff, E., de Riese, W., Eifinger, M., Pethke, J. & Jones, U. Prostate-specific antigen-comparative clinical appreciation of a serodiagnostic measure after 8 years of experience. World J. Urol. 7, 12-16 (1989). (Pubitemid 19140817)
7. Cooner, W. H. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 143, 1146-1154 (1990). (Pubitemid 20193057)
8. Aly, M., Wiklund, F. & Grönberg, H. Early detection of prostate cancer with emphasis on genetic markers 1. Acta. Oncol. 50 (Suppl. 1), 18-23 (2011).
9. Wright, J. L. & Lange, P. H. Newer potential biomarkers in prostate cancer. Rev. Urol. 9, 207-213 (2007).
10. Thorpe, A. & Neal, D. Benign prostatic hyperplasia. Lancet 361, 1359-1367 (2003). (Pubitemid 36514874)
11. De Nunzio, C. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 60, 106-117 (2011).
12. Gulati, R. et al. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol. Biomarkers Prev. 20, 740-750 (2011).
13. Auprich, M. et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol. 60, 1045-1054 (2011).
14. Auprich, M. et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur. Urol. 59, 96-105 (2011).
15. Oon, S. F., Pennington, S. R., Fitzpatrick, J. M. & Watson, R. W. Biomarker research in prostate cancer-towards utility, not futility. Nat. Rev. Urol. 8, 131-138 (2011).
16. Chodak, G. W., Keller, P. & Schoenberg, H. W. Assessment of screening for prostate cancer using the digital rectal examination. J. Urol. 141, 1136-1138 (1989). (Pubitemid 19124217)
17. Gosselaar, C., Kranse, R., Roobol, M. J., Roemeling, S. & Schröder, F. H. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68, 985-993 (2008). (Pubitemid 351794163)
18. Vickers, A. J. et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated PSA: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 116, 2612-2620 (2010).
19. You, J. et al. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit. Rev. Oncol. Hematol. 73, 10-22 (2010).
20. Edge, S. B. et al. (eds) AJCC Cancer Staging Manual (Springer, New York, 2010).
21. Gleason, D. F. & Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111, 58-64 (1974).
22. Schmidt, C. Gleason scoring system faces change and debate. J. Natl Cancer Inst. 101, 622-629 (2009).
23. Cheng, L., Montironi, R., Bostwick, D. G., Lopez-Beltran, A. & Berney, D. M. Staging of prostate cancer. Histopathology 60, 87-117 (2012).
24. Bostwick, D. G. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 995-1000 (2000). (Pubitemid 30602040)
25. Shen, M. M. & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
26. Porkka, K. P. & Visakorpi, T. Molecular mechanisms of prostate cancer. Eur. Urol. 45, 683-691 (2004). (Pubitemid 38638387)
27. Reynolds, M. A. Molecular alterations in prostate cancer. Cancer Lett. 271, 13-24 (2008).
28. Ho, C. M. & Weilbaecher, A. Patents versus patients: must we choose? Ann. Health Law 18, i-xv (2009).
29. Mejer, M. & van Pottelsberghe de la Potterie, B. Patent backlogs at USPTO and EPO: systemic failure vs deliberate delays. World Patent Inf. 33, 122-127 (2011).
30. Sternitzke, C. Reducing uncertainty in the patent application procedure-insights from invalidating prior art in European patent applications. World Patent Inf. 31, 48-53 (2009).
31. Madu, C. O. & Lu, Y. Novel diagnostic biomarkers for prostate cancer. J. Cancer 1, 150-177 (2010).
32. Busse U., Chypre, C. & Fradet, Y. PCA3 messenger RNA species in benign and malignant prostate tissues. US Patent 7,368,545 (2010)
33. Daly, J. R., Jost, M., Reynolds, M. A., Groskopf, J. & Rittenhouse, H. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 301, 1-6 (2011).
34. PROGENSA®PCA3 featured at European Association of Urology congress in Paris. DiagnoCure [online], http://www.diagnocure.com/docs/news/358.2012-02-29- CUR-PressRelease.pdf (2012).
35. Pettersson, K., Lilja, H., Lövgren, T. & Niemelä, P. Antibody, immunoassay and method for prostate cancer detection. US Patent 7,872,104 (2001).
36. Vickers, A. J. et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med. 6, 19-29 (2008).
37. Hessels, D., Verhaegh, G., Schalken, J. A. & Witjes, A. J. mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer. US Patent 7,960,109 (2005).
38. Zhang, Z., Barnhill, S. D., Madyastha, R. & Zhang, H. Methods for diagnosing cancer by measuring creatine kinase. US Patent 6,309,816 (1998).
39. Tewari, P. Detection of PSA-.α.2-macroglobulin complex in a biological fluid. US Patent 6,548,260 (1998).
40. Griffiths, K. & Turkes, A. T. Detection of prostate cancer measuring PSA/IGF1 ratio. European Patent 1,218,749 (2000).
41. Duan, X., Kim, N. & Wolfert, R. L. Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers. US Patent 7,560,531 (2004).
42. Stearns, M., Hu, Y. & Wang, M. Prostate cancer-related compositions, methods and kits based on DNA macroarray proteomics platforms. US Patent 7,939,274 (2010).
43. Saatcioglu, F. Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. US Patent 7,611,892 (2006).
44. Sidransky, D. Method of detection of prostate cancer. US Patent 7,524,633 (2007).
45. Jerónimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747-1752 (2001). (Pubitemid 33130264)
46. Tsujikawa, K., Yamamoto, H. & Konishi, N. Method for diagnosis of prostate cancer. European Patent 1,862,804 (2006).
47. Castellani, L. W. et al. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J. Biol. Chem. 283, 11633-11644 (2008).
48. Semmes, J. O., Malik, G. & Ward, M. D. Apolipoprotein AII isoform as a biomarker for prostate cancer. European Patent 1,838,867 (2006).
49. An, G. & Veltri, R. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer. US Patent 7,993,830 (2007).
50. Thompson, T. C. Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin. US Patent 7,462,491 (2004).
51. Golub, T. R., Febbo, P. G., Ross, K. N. & Sellers, W. R. Prostate cancer diagnosis and outcome prediction by expression analysis. US Patent 7,501,248 (2005).
52. Penny, K. L. et al. mRNA expression signature of gleason grade predicts lethal prostate cancer. J. Clin. Oncol. 29, 2391-2396 (2011).
53. Tempst, P. & Villanueva, J. Methods of detection of cancer using peptide profiles. US Patent 7,972,770 (2006).
54. Mikolajczyk, S. D., Wang, T. J., Rittenhouse, H. G., Wolfert, R. L. & Slawin, K. Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such. US Patent 6,482,599 (1999).
55. Amano, J., Hirano, K. & Sugimoto, I. Method of distinguishing prostate cancer from benign prostatic hypertrophy. US Patent 8,030,085 (2008).
56. Chudin, E., Lozach, J., Fan, J. & Bibikova, M. Gene expression profiles to predict relapse of prostate cancer. US Patent 7,914,988 (2007).
57. Keller, E. T. & Fu, Z. Systems and methods for detecting and regulating metastasis. US Patent 7,407,763 (2005).
58. Bao, L. & Wang, D. G. Pin 1 as a marker for prostate cancer. US Patent 7,592,145 (2006).
59. Siegler, K. M. Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer. US Patent 7,361,474 (2003).
60. Reed, J. C. & Krajewske, S. Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides. US Patent 7,704,700 (2003).
61. O'Riordan, M. X. D., Bauler, L. D., Scott, F. L. & Duckett, C. S. Inhibitor of apoptosis (IAP) proteins in eukaryotic evolution and development: a model of thematic conservation. Dev. Cell 15, 497-508 (2008).
62. Rubin, M. A. & DeMichelis, F. Biomarkers for predicting prostate cancer progression. US Patent 7,803,552 (2009).
63. Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913-923 (2004). (Pubitemid 38544150)
64. Li, C. & Wong, W. H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl Acad. Sci. USA 98, 31-36 (2001). (Pubitemid 32095858)
65. Wang, D., Herzenberg, L. A., Peehl, D. M. & Herzenberg, L. A. Prostate cancer glycan markers and autoantibody signatures. US Patent 7,981,625 (2009).
66. Neagu, M., Constantin, C., Tanase, C. & Boda, D. Patented biomarker panels in early detection of cancer. Recent Pat. Biomark. 1, 10-24 (2011).
67. US Department of Heath and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. Guidance for industry: pharmacogenomic data dubmissions [online], http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm126957.pdf (2005).
68. European Medicines Agency. Guideline on the validation of bioanalytical methods [online], http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/08/WC500109686.pdf (2011).
69. US Department of Heath and Human Services, FDA, Center for Drug Evaluation and Research & Center for Veterinary Medicine. Guidance for industry: bioanalytical method validation [online], http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm070107.pdf (2001).
70. Valentin, M. A., Ma, S., Zhao, A., Legay, F. O. & Avrameas, A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J. Pharm. Biomed. Anal. 55, 869-877 (2011).
71. Swanson, G. P., Yu, C., Kattan, M. W. & Hermans, M. R. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology 78, 105-109 (2011).
72. Specht, M. C., Kattan, M. W., Gonen, M., Fey, J. & Van Zee, K. J. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654-659 (2005). (Pubitemid 41126095)
73. Vickers, A. J. Prediction models in cancer care. CA Cancer J. Clin. 61, 315-326, (2011).
74. Garofolo, F., Smeraglia, J., Briggs, R., Seymour, M. & Hill, H. Conference report: discussion on harmonization and globalization of bioanalytical guidances at the 19th International Reid Bioanalytical Forum. Bioanalysis 3, 2717-2720 (2011).
75. US Department of Heath and Human Services, FDA, Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (2007).
76. Chowdhury, F., Williams, A. & Johnson, P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 340, 55-64 (2009).
77. Kruse, N., Schulz-Schaeffer, W. J., Schlossmacher, M. G. & Mollenhauer, B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of αsynuclein and other proteins in cerebrospinal fluid. Methods http://dx.doi.org/10.1016/j.ymeth.2012.03.016
78. Semenuk, M. A. et al. Translating cancer biomarker discoveries to clinical tests: what should be considered? Recent Pat. Biomark. 1, 222-240 (2011).
79. Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 26, 1320-1328 (2009).
80. Stephenson, A. J. et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol. 24, 3973-3978 (2006). (Pubitemid 46630746)
81. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268-278 (2008). (Pubitemid 351430866)
82. Horwitz, E. M. et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J. Urol. 173, 797-802 (2005). (Pubitemid 40239344)